Analyzing tumor and blood samples to understand DNA changes in lung cancer patients
Official title: EGFR Pathway Mutations in Lung Cancer Patient Tumors and Blood
Run by University of California, Davis · NCT00899405 · Data updated 2026-11-12
This study looks at tumor and blood samples from lung cancer patients to see if certain DNA changes can help us understand their treatment outcomes better.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 800 (estimated) |
| Sponsor | University of California, Davis Academic / other |
| Locations | 1 site (Sacramento, California) |
| Status | Recruiting |
| Started | May 19, 2004 |
| Main results expected | May 2034 |
| Study ends | May 2034 |
| Registry record updated | June 25, 2026 |
| Trial ID | NCT00899405 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients with histologically or cytologically confirmed lung cancer.
✕Probably not a fit
Patients without a confirmed diagnosis of lung cancer or those who have not received prior EGFR inhibitors may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study focuses on analyzing tumor tissue and blood samples from patients diagnosed with lung cancer to investigate DNA changes, specifically looking at mutations in the EGFR pathway. By examining these samples, researchers aim to correlate the presence of EGFR mutations with clinical outcomes in patients. The study utilizes PCR techniques to detect these mutations, providing insights that may enhance understanding of lung cancer biology and treatment responses.
Why it matters
Potential benefit: If successful, this study could lead to improved identification of biomarkers that inform treatment decisions for lung cancer patients.
How similar studies have gone: Other studies examining DNA mutations in lung cancer have shown promising results, indicating that this approach is supported by prior research.
Who can join: the full rules
Show full inclusion / exclusion criteria
DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed lung cancer PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * May have received prior EGFR inhibitors
Where it's running
-
University of California Davis Cancer Center
Sacramento, California, United States Recruiting
Study contacts
- Principal investigator: Jonathan Riess, MD — University of California, Davis
- Study coordinator: Office of Clinical Research
- Email: OCRReferral@health.ucdavis.edu
- Phone: 916-382-6970
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
ePRO in advanced lung cancer: emotional distress, brain metastasis, and symptom burden
This study tests how patients with advanced lung cancer—some with brain metastases—report emotional distress and symptoms over time using electronic questionnaires.
-
Urine VOC Test to Detect Lung Cancer in Never Smokers
A urine test that looks for volatile compounds is tested to see if it can help detect lung cancer in adults who have never smoked.
-
SI-B036 safety test in advanced and metastatic solid tumors
This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.
-
Guaraná Supplement for Cancer-Related Fatigue in People Undergoing Treatment
This study tests whether taking guaraná capsules helps reduce cancer-related fatigue and improve quality of life in adults with breast, lung, colorectal, or gastric cancer who are actively receiving treatment.
-
ENPP1/cGAS and FAP in Solid Tumors in Vietnamese Patients
This Vietnam-based study will test ENPP1, cGAS, and FAP expression in archived tumor samples from Vietnamese adults with solid cancers using immunohistochemistry.
-
Olive oil before lung cancer surgery to see if it lowers chylothorax
This study tests whether drinking 40 mL of extra-virgin olive oil a few hours before lung cancer surgery can reduce chylothorax after tumor removal.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.